ABBV is trading at $232.10 (+3.65%), following UBS raising its price target to $240 from $220.
- The stock builds on yesterday's close of $223.93 (+1.70%) after UBS maintained a Neutral rating on January 7, 2026.
- Average analyst targets stand at $244.85, implying a modest 9% upside potential.
- Healthcare sector strength provides additional tailwinds amid mixed broader markets.